Europe Approves First-Ever Treatment for Rett Syndrome

For the first time ever, families in Europe have an approved treatment option for Rett syndrome, a severe genetic condition that can rob young girls of their ability to speak, walk, and care for themselves.

The European Commission just granted approval for DAYBU, a medication that treats the neurobehavioral symptoms of Rett syndrome in patients five years and older. Until now, families had no approved therapies to turn to.

Rett syndrome is a rare neurological disorder that predominantly affects girls, causing profound impairments in communication, motor skills, and daily functioning. The condition typically appears in early childhood and progressively worsens over time.

Melbourne-based Neuren Pharmaceuticals developed the treatment, called trofinetide, which is already helping patients in the United States, Canada, and Israel. Jon Pilcher, Neuren's chief executive, called the approval "particularly rewarding" given the company's commitment to serious neurological disorders with no existing treatments.

DAYBU will launch first in Germany in early fourth quarter of 2026, with rollout across all 27 EU member states to follow. Acadia Pharmaceuticals, which licensed the drug worldwide from Neuren, will handle the European launch.

The Ripple Effect

This approval represents more than just one new medication. It opens doors for thousands of families who have been managing Rett syndrome without any approved therapeutic options.

The success of DAYBU also fuels hope for other rare neurological conditions. Neuren is already advancing another investigational treatment through clinical trials for Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome.

The company is currently running a Phase 3 trial testing their next candidate in children aged three to 12 with Phelan-McDermid syndrome. They're also developing treatments for brain injuries that can occur during or shortly after birth.

For parents who have watched their daughters lose abilities they once had, this approval means something profound: validation that research continues, progress happens, and help is coming.